Key Highlights
- LIS Technologies Inc. successfully closed its third consecutive oversubscribed funding round, raising $11.93 million, bringing total capital raised to over $47 million.
- The funding will accelerate development and scale-up of the company’s patented U.S.-origin CRISLA laser technology for producing low-enriched uranium and vital medical isotopes used in therapies and diagnostics.
- The company aims to strengthen the domestic supply chain for nuclear materials and medical isotopes, supporting both clean energy production and critical healthcare applications.
Innovative CRISLA Technology to Impact Medical Therapies
The company’s proprietary Condensation Repression Isotope Selective Laser Activation (CRISLA) technology is uniquely positioned to transform both nuclear fuel production and medical isotope manufacturing. Medical isotopes produced using CRISLA are essential components in diagnostic imaging and targeted radiotherapy treatments for various cancers and other diseases. By advancing a U.S.-origin, patented technology platform, LIST aims to reduce reliance on foreign suppliers and enhance the reliability and availability of these critical materials within the healthcare sector.
Strengthening Domestic Supply Chains for Healthcare and Clean Energy
With increasing global demand for medical isotopes and nuclear materials, the need for robust domestic production capabilities has never been greater. LIS Technologies’ advancements directly address this challenge by streamlining isotope separation processes with greater precision and efficiency than traditional methods. This positions LIST as a key player in supporting the U.S. healthcare system’s ongoing needs for medical isotopes used in cancer therapies, cardiology diagnostics, and other essential medical applications.
Strategic Growth and Future Outlook
The capital raised will accelerate development efforts, including engineering, integration, and testing of the company’s Test Demonstration Facility at its Oak Ridge, TN laboratories. Additional investments will enable LIST to further develop proprietary laser systems within the U.S., optimize isotope production techniques, and diversify into other stable and medical isotopes.
“By delivering a reliable supply of high-quality medical isotopes domestically, we are supporting the medical community’s capacity to diagnose and treat patients more effectively,” said Christo Liebenberg, CEO of LIS Technologies. “Our technology’s ability to produce LEU for nuclear energy and critical medical isotopes in the same platform makes it a dual-use innovation with profound implications for energy security and healthcare advancement.”
As LIS Technologies continues its path toward industrial scale demonstration and commercialization, the company remains committed to helping the medical community access essential isotopes vital for life-saving therapies and diagnostics.
By